Tesofensine vs Compounded Tirzepatide
A side-by-side research comparison of Tesofensine and Compounded Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Tesofensine | Compounded Tirzepatide |
|---|---|---|
| Full name | Tesofensine (Triple Monoamine Reuptake Inhibitor) | Compounded Tirzepatide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Compounded medication |
| Mechanism | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. | Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss. |
| Molecular weight | 329.4 Da | 4813.45 Da |
| Half-life | 8-10 days | ~5 days |
| Bioavailability | High (oral ~93%) | ~80% subcutaneous |
| Typical dose | 0.25-0.5 mg | 2.5-15 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Compounded Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Dual incretin pathway activation
- Better muscle preservation
- Improved A1c
- Cardiovascular protection
- Reduced insulin resistance
Related comparisons
Research and educational reference only. Not medical advice.